(2R,3R,4R,5R,6S)-2-Hydroxymethyl-6-methyl-tetrahydro-pyran-3,4,5-triol | 30628-01-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4R,5R,6S)-2-Hydroxymethyl-6-methyl-tetrahydro-pyran-3,4,5-triol
• 英文别名: (2R,3R,4R,5R,6S)-2-(hydroxymethyl)-6-methyloxane-3,4,5-triol
• CAS: 30628-01-4
• 化学式: C₇H₁₄O₅
• 分子量: 178.185
• InChiKey: VUWMDLRKEQUSPZ-MLKOFDEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Novel SGLT inhibitors
  申请人：Nomura Sumihiro

  公开号：US20080027014A1

  公开（公告）日：2008-01-31

  Novel compounds of formula (A) or a pharmaceutically acceptable salt thereof: wherein symbols are as defined in claims, which are useful as SGLT inhibitors and for treatment of diabetes and related diseases.

  化合物的新颖结构式（A）或其药学上可接受的盐： 其中符号如权利要求中所定义，这些化合物可用作SGLT抑制剂，用于治疗糖尿病及相关疾病。
• CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US20150238597A1

  公开（公告）日：2015-08-27

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

  本发明涉及合成和生物评价一种新型基于碳水化合物的疫苗的领域。这种新疫苗由多模块结构组成，可以将疫苗应用于各种病原体。该方法允许制备针对所有表达免疫原碳水化合物抗原的病原体的疫苗。由于不需要将抗原碳水化合物与蛋白质结合，所以结合疫苗尤其耐热稳定。无需冷藏，这是基于蛋白质的疫苗的一个主要缺点。
• [EN] ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES ANTICORPS ANTI-B7-H3
  申请人：INTOCELL INC

  公开号：WO2021260438A1

  公开（公告）日：2021-12-30

  The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

  本公开涉及抗体药物结合物（ADCs），其中一个或多个活性剂通过连接剂与抗B7-H3抗体结合。连接剂可能包括一个单位，将活性剂共价连接到抗体上。本公开进一步涉及特异性结合B7-H3的单克隆抗体和抗原结合片段、变体、多聚体版本或双特异性抗体，以及在各种治疗、诊断和预防适应症中制备和使用这些抗B7-H3抗体和抗原结合片段的方法。
• Rebaudioside Analogs
  申请人：PepsiCo, Inc.

  公开号：US20180016291A1

  公开（公告）日：2018-01-18

  The present disclosure provides novel compounds that are steviol derivatives. The compounds generally can be characterized by a structure according to Formula I: wherein A 1 , L 1 , and G 1 are described herein. Also provided are sweetener compositions comprising the compound described herein either as a sweetener or a sweetener enhancer. Additionally, the compound or the sweetener composition can be included in a product such as a beverage product or a food product, which can reduce the amount of sweetener in the product required to achieve the same sweetness level in an otherwise identical product not including the compound or the sweetener composition.

  本公开提供了一些新颖的化合物，这些化合物是史蒂维醇衍生物。这些化合物通常可通过以下式I所示的结构来表征：其中A1、L1和G1如本文所述。还提供了包含所述化合物的甜味剂组合物，可以作为甜味剂或增甜剂。此外，该化合物或甜味剂组合物可以包含在产品中，例如饮料产品或食品产品中，可以减少产品中所需的甜味剂量，以达到在另一种不包含该化合物或甜味剂组合物的相同产品中所需的甜度水平。
• Compounds and methods for the inhibition of the expression of VCAM-1
  申请人：——

  公开号：US20020188118A1

  公开（公告）日：2002-12-12

  This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

  本发明涉及用于抑制VCAM-1表达的方法和组合物，特别是用于治疗由VCAM-1介导的疾病，包括心血管和炎症性疾病。